Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis

Annals of Neurology

Volumn 46, Issue 4, 1999, Pages 559-567

  Aissaoui, Abderrahim ^a   Klingel Schmitt, Isabelle ^a   Couderc, Jacques ^c   Chateau, Danielle ^d   Romagne, Francois ^e   Jambou, Florence ^a   Vincent, Angela ^f   Levasseur, Philippe ^b   Eymard, Bruno ^d   Maillot, Marie Christine ^c   Galanaud, Pierre ^c   Berrih Aknin, Sonia ^a   Cohen Kaminsky, Sylvia ^a,g  

^a CNRS   (France)

^b Dept Chir Thoracique Hop Marie L ^*  (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e Immunotech   (France)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; GAMMA INTERFERON; HLA DR3 ANTIGEN; INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR;

ADOLESCENT; ADULT; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOTHERAPY; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; RECEPTOR GENE;

ADOLESCENT; ADULT; ANIMALS; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, SCID; MOTOR ENDPLATE; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CHOLINERGIC;

EID: 0032834013     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199910)46:4<559::AID-ANA3>3.0.CO;2-S     Document Type: Article

References (45)

1. Engel WK, Festoff BW, Patten BM, et al. Myasthenia gravis. Ann Intern Med 1974;81:225-246
2. Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol 1978;9:495-515
3. Molnar J, Szobor A. Myasthenia gravis: effect of thymectomy in 425 patients: a 15-year experience. Eur J Cardiothorac Surg 1990;4:8-14
4. Schluep M, Willcox N, Vincent A, et al. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann Neurol 1987;22:212-222
5. Wakkach A, Guyon T, Bruand C, et al. Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J Immunol 1996;157:3752-3760
6. Vincent A, Scadding GK, Thomas HC, Newsom-Davis J. In vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis. Lancet 1978;1:305-307
7. Leprince C, Cohen-Kaminsky S, Berrih-Aknin S, et al. Thymic B cells from myasthenia gravis patients are activated B cells: phenotypic and functional analysis. J Immunol 1990;145: 2115-2122
8. Hohlfeld R, Toyka KV, Heininger K, et al. Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature 1984;310:244-246
9. Melms A, Chrestel S, Schalke BC, et al. Autoimmune T lymphocytes in myasthenia gravis: determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J Clin Invest 1989;83:785-790
10. Truffault F, Cohen-Kaminsky S, Khalil I, et al. Altered intrathymic T-cell repertoire in human myasthenia gravis. Ann Neurol 1997;41:731-741
11. Moulian N, Bidault J, Truffault F, et al. Thymocyte Fas expression is dysregulated in myasthenia gravis patients with anti-acetylcholine receptor antibody. Blood 1997;89:3287-3295
12. Fuller KA, Kanagawa O, Nahm MH. T cells within germinal centers are specific for the immunizing antigen. J Immunol 1993;151:4505-4512
13. Tary-Lehman M, Saxon A, Lehmann PV. The human immune system in hu-PBL-SCID mice. Immunol Today 1995;16:529-533
14. Schonbeck S, Padberg F, Hohlfeld R, Wekerle H. Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice: a new model of myasthenia gravis. J Clin Invest 1992;90:245-250
15. Martino G, DuPont BL, Wollmann RL, et al. The human-severe combined immunodeficiency myasthenic mouse model: a new approach for the study of myasthenia gravis. Ann Neurol 1993;34:48-56
16. Vieira ML, Caillat-Zucman S, Gajdos P, et al. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J Neuroimmunol 1993;47:115-222
17. Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 1971;38:497-537
18. Llorente L, Zou W, Levy Y, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995;181: 839-844
19. 125I-labeled alpha-bungarotoxin binding at mouse motor endplates. Proc Natl Acad Sci USA 1974;71:1376-1378
20. Guyon T, Wakkach A, Poea S, et al. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles: evidence for a compensatory mechanism triggered by receptor loss. J Clin Invest 1998;102:249-263
21. Zou W, Durand-Gasselin I, Dulioust A, et al. Quantification of cytokine gene expression by competitive PCR using a colorimetric assay. Eur Cytokine Netw 1995;6:257-264
22. Estaquier J, Idziorek T, Zou W, et al. T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. J Exp Med 1995;182:1759-1767
23. Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977;52:267-280
24. Protti MP, Manfredi AA, Horton RM, et al. Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol Today 1993;14:363-368
25. Conti-Fine BM, Navaneetham D, Karachunski PI, et al. T cell recognition of the acetylcholine receptor in myasthenia gravis. Ann NY Acad Sci 1998;841:283-308
26. Berrih-Aknin S, Cohen-Kaminsky S, Lepage V, et al. T-cell antigenic sites involved in myasthenia gravis: correlations with antibody titre and disease severity. J Autoimmun 1991;4:137-153
27. Raju R, Navaneetham D, Protti MP, et al. Acetylcholine receptor-specific CD4+ T cells in myasthenia gravis patients have individual, but restricted TCR V beta usage. Ann NY Acad Sci 1998;841:324-328
28. Melms A, Oksenberg JR, Malcherek G, et al. T-cell receptor gene usage of acetylcholine receptor-specific T-helper cells. Ann NY Acad Sci 1993;681:313-314
29. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980;103:579-601
30. Wack A, Ladyman HM, Williams O, et al. Direct visualization of thymocyte apoptosis in neglect, acute and steady-state negative selection. Int Immunol 1996;8:1537-1548
31. Dessureault S, Shpitz B, Alloo J, et al. Physiologic human T-cell responses to OKT3 in the human peripheral blood lymphocyte-severe combined immunodeficiency mouse model. Transplantation 1997;64:811-816
32. Wang ZQ, Dudhane A, Orlikowsky T, et al. CD4 engagement induces Fas antigen-dependent apoptosis of T cells in vivo. Eur J Immunol 1994;24:1549-1552
33. Coppola V, Veronesi A, Indraccolo S, et al. Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice. IV. Differential activation of human Th1 and Th2 lymphocytes and influence of the atopic status on lymphoma development. J Immunol 1998;160:2514-2522
34. Launois P, Maillard I, Pingel S, et al. IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 1997;6:541-549
35. Groux H, O'Garra A, Bigler M, Rouleau M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-742
36. Mieza MA, Itoh T, Cui JQ, et al. Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol 1996;156:4035-4040
37. Sumida T, Sakamoto A, Murata H, et al. Selective reduction of T cells bearing invariant V alpha 24 J alpha Q antigen receptor in patients with systemic sclerosis. J Exp Med 1995;182:1163-1168
38. Moiola L, Galbiati F, Martino G, et al. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur J Immunol 1998;28:2487-2497
39. Balasa B, Deng C, Lee J, et al. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J Immunol 1998;161:2856-2862
40. Roses AD, Olanow CW, McAdams MW, Lane RJ. No direct correlation between serum anti-acetylcholine receptor antibody levels and clinical state of individual patients with myasthenia gravis. Neurology 1981;31:220-224
41. Pestronk A, Drachman DB, Self SG. Measurement of junctional acetylcholine receptors in myasthenia gravis: clinical correlates. Muscle Nerve 1985;8:245-251
42. Vandenbark AA, Chou YK, Whitham R, et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med 1996;2:1109-1115
43. Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989;341: 541-544
44. Haqqi TM, Qu XM, Anthony D, et al. Immunization with T cell receptor V beta chain peptides deletes pathogenic T cells and prevents the induction of collagen-induced arthritis in mice. J Clin Invest 1996;97:2849-2858
45. Moreland LW, Heck LW Jr, Koopman WJ, et al. V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study. J Rheumatol 1996;23:1353-1362